SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers faces significant pressure after Novo Nordisk filed a lawsuit for alleged illegal marketing of copycat GLP-1 drugs, prompting Hims to halt sales of its compounded semaglutide pill. The investment community is sharply divided, with some calling it "karma" for IP infringement, while others view it as an "oversold" market overreaction, anticipating a potential short squeeze.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

ELF Beauty is trending after strong earnings and raised guidance were overshadowed by a market reaction many attribute to a recent Super Bowl commercial. The community is actively discussing this perceived overreaction, with many viewing the subsequent dip as a compelling buying opportunity.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending due to reports of an SEC review into its accounting practices and the abrupt departures of its CFO and General Counsel, triggering a steep sell-off driven by concerns over financial integrity; however, a vocal part of the community views the severe decline as an oversold opportunity for a rebound.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after its Q4 earnings report, which, despite a revenue miss, beat EPS estimates and outlined an optimistic outlook for 2026, including the expiration of a value-destructive slab contract and ongoing POSCO partnership discussions. While some in the community view the stock's subsequent dip as a buying opportunity driven by these future catalysts, others remain deeply skeptical about its performance and management.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending after announcing a $5.8 billion all-stock acquisition of Valaris, a move generating buzz as a strategic consolidation to create an offshore drilling leader, aiming to boost cash flow and benefit from an emerging industry upcycle, despite some investor caution regarding potential share dilution.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com's stock is plummeting after issuing weaker-than-expected guidance, sparking widespread investor fears about AI disrupting the traditional software business model. The community is sharply divided, with many fearing obsolescence for SaaS platforms while others view the significant drop as an oversold opportunity.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as Morgan Stanley initiates coverage with an Overweight rating and a $37 price target, validating its strategic pivot to AI/HPC data centers amidst increasing hyperscaler capital expenditure. The community is actively discussing potential for a significant short squeeze and further contracts with major tech partners.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to a significant stock drop following its Q4 earnings report, which, despite showing profitability and prudent risk management, included a revenue miss and cautious guidance. The community is actively debating if the sell-off is an overreaction, viewing it as a potential buying opportunity given the company's strong fundamentals and AI-powered model, while others remain concerned about the broader fintech sector's volatility.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as community discussion heats up around the recent inauguration of its Eagle Line, a significant step toward scalable solid-state battery production. While bulls anticipate potential OEM partnership announcements and licensing deals, others express frustration over the stock's performance and await concrete revenue details from the upcoming earnings report.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending with high volatility as its February 8th PDUFA date for RGX-121 approaches, amidst a recent clinical hold on the therapy and a related program due to a patient's brain tumor, leaving the community sharply divided on whether a significant drop from a Complete Response Letter or a delay is more likely.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are currently covering the firm, Marketbeat.com reports. One...

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights GUTS

The DJS Law Group announces that it is investigating claims on behalf of investors of Fractyl Health, Inc. (Fractyl Health or the Company) (NASDAQ: GUTS) for violations of the securities laws...

Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain

Fractyl Health (NASDAQ:GUTS) presented prospective, randomized, double-blind, controlled six-month data from its REMAIN-1 midpoint cohort pilot study, highlighting results the company said support...

<ul class="summary-bullets"><li>The results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial.&nbsp;</li><li>Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles.</li><li>Patient-reported outcomes also indicated reduced cravings for sweet foods.</li></ul>Fractyl Health, Inc. (GUTS) announced on Thursday positive six-month findings from its ongoing REMAIN-1 Midpoint Cohort, a study evaluating Revita for weight maintenance after patients discontinue GLP-1 therapy.The six-month data, covering 40 participants, suggest that Revita helps limit weight regain following GLP-1 discontinuation, with treated patients regaining 4.5% of weight versus 7.5% in the sham group.<h2 class="st-heading-2">Midpoint Study Shows Promising Results</h2>An exploratory analysis of those who lost above-median weight during the GLP-1 run-in showed a 70% relative reduction in post-GLP-1 weight regain for Revita-treated participants compared with sham.&nbsp;These results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial. Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles, including higher HDL cholesterol and a lower triglyceride-to-HDL ratio.&nbsp;Patient-reported outcomes also indicated reduced cravings for sweet foods, suggesting that the device may influence appetite and metabolism through gut-mediated mechanisms.However,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">Fractyl Health's stock</a> plummeted 63% in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Despite the fall in the stock’s price, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_29_085922_png_07f795b807.webp" alt="GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits" width="930" height="110"><figcaption>GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the product that reduces sweet cravings could be extremely profitable, highlighting huge market potential.<stembedurl>https://stocktwits.com/BioRich/message/643264512</stembedurl>Another user said they trusted the management and would hold the stock.&nbsp;<stembedurl>https://stocktwits.com/CocoPeechu/message/643264755</stembedurl>Revita, the main product from Fractyl Health, is meant to reshape the lining of the small intestine through a single, minimally invasive procedure. The FDA has granted Revita Breakthrough Device designation to help people maintain weight after stopping GLP-1 treatments.The company also outlined upcoming catalysts, including one‑year cohort readouts and pivotal REMAIN‑1 data later this year, which could support a future U.S. marketing application.GUTS stock has declined by over 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-now-stock-is-falling/cmyifBjR4KZ">NOW Stock Falls 9% After Q4 Beat: Why Have Analysts Cut Price Targets?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? 

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

Equity

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.


HC Wainwright Forecasts Fractyl Health FY2030 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Fractyl Health in a research report issued to clients and investors on...

Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Expands By 24.0%

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 11,893,654 shares, a growth...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat reports. One...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat reports...

Fractyl Health (NASDAQ:GUTS) CEO Acquires $19,998.72 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the stock in a transaction on Thursday, December 4th. The stock was acquired at an average cost of...

Insider Buying: Fractyl Health (NASDAQ:GUTS) CEO Buys 10,416 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the firm's stock in a transaction that occurred on Thursday, December 4th. The shares were acquired...

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GUTS News

GUTSFractyl Health Inc.